found Documents: 865

Announcements & Press Releases, Group | 28 Jun 2019

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“

Download Announcement (PDF)

Announcements & Press Releases, Group | 27 Jun 2019

Chi-Med Announces Secondary Offering of American Depositary Shares

1 item

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jun 2019

Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

1 item

London: Friday, June 14, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tum

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 12 Jun 2019

Block Admission Applications and Total Voting Rights

1 item

London: Wednesday, June 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 6 Jun 2019

Disclosure Update

1 item

London: Thursday, June 6, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connec

Download Announcement (PDF)

Announcements & Press Releases, Group | 29 May 2019

Results of Extraordinary General Meeting

1 item

London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 22 May 2019

Grant of Share Options under Share Option Scheme

1 item

London: Wednesday, May 22, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting

View Announcement (PDF)

Announcements & Press Releases, Group | 3 May 2019

Notice of Extraordinary General Meeting and Shareholders' Circular

1 item

London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 24 Apr 2019

Results of Annual General Meeting

1 item

London: Wednesday, April 24, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 24, 2019 were duly

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 15 Apr 2019

Disclosure Update

1 item

London: Monday, April 15, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed an application (the “Listing Application”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connection

Download Announcement (PDF)

Announcements & Press Releases, Group | 15 Apr 2019

Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong: Monday, April 15, 2019: Hutchison China MediTech

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2019

Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

1 item

London: Friday, March 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Mar 2019

Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting

1 item

Press Release London: Thursday, March 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of Cancer Research (AACR)

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 25 Mar 2019

Vesting of awards under the Long Term Incentive Plan

1 item

London: Monday, March 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2018 annual report of Chi-Med on March 21 2019, the following awards granted under the Long Term Incent

Download Announcement (PDF)

Announcements & Press Releases, Group | 21 Mar 2019

2018 Annual Report and Notice of Annual General Meeting

1 item

London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders

Download Announcement (PDF)

Announcements & Press Releases, Group | 11 Mar 2019

Publication of Form 20-F

1 item

London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r

View Form 20-F (PDF)

Announcements & Press Releases, Group | 11 Mar 2019

Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

1 item

London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 12 Feb 2019

Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium

1 item

London: Tuesday, February 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in

Download Press Release (PDF)

Announcements & Press Releases, Group | 8 Feb 2019

Chi-Med to Announce 2018 Final Results

1 item

London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr

Download Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 7 Jan 2019

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

1 item

Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2018

Blocklisting Six Monthly Return

1 item

London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2018

Total Voting Rights

1 item

London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

1 item

– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all development costs of life cycle indications in

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

1 item

– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Dec 2018

TR-1: Form for notification of major holdings

1 item

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Nov 2018

Total Voting Rights

1 item

London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Nov 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

1 item

London: Thursday, November 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) a

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 Nov 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

1 item

London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the

Download Press Release (PDF)

Oncology / Immunology | 20 Nov 2018

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

1 item

Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Nov 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

1 item

– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – London: Friday, November 16, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the outcome of

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Oct 2018

Total Voting Rights

1 item

London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 22 Oct 2018

Grant of Share Options under Share Option Scheme

1 item

London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Oct 2018

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

1 item

London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 5 Oct 2018

Appointment of HSBC Bank plc as Joint Corporate Broker in London

1 item

London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Sep 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

1 item

– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased overall survival versus placebo – – F

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Aug 2018

Total Voting Rights

1 item

London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Aug 2018

Grant of Share Options under Share Option Scheme

1 item

London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin

View Announcement (PDF)

Announcements & Press Releases, Group | 27 Jul 2018

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Jul 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

1 item

London: Monday, July 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors (“NET”) patients and in biliary tract cancer (�

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2018

Total Voting Rights

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2018

Blocklisting Six Monthly Return

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)

Download Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 29 Jun 2018

Chi-Med to Announce 2018 Half-Year Financial Results

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jun 2018

Grant of Share Options under Share Option Scheme

1 item

London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2018

Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

1 item

Press Release – Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target toxicities compared to other targeted t

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 31 May 2018

Total Voting Rights

1 item

London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e

Download Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 11 May 2018

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

Press Release London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe

Announcements & Press Releases, Regulatory Notice | 30 Apr 2018

Total Voting Rights

1 item

London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 27 Apr 2018

Results of AGM Meeting

1 item

London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Apr 2018

Block Admission

1 item

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Apr 2018

Grant of Share Options under Share Option Scheme

1 item

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting

View Announcement (PDF)

1 2 3 4 5 6 7 8 9

11 12 13 14 15 16 17 18